Literature DB >> 21115979

Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome.

Andrea Rinaldi1, Michael Mian, Ekaterina Chigrinova, Luca Arcaini, Govind Bhagat, Urban Novak, Paola M V Rancoita, Cassio P De Campos, Francesco Forconi, Randy D Gascoyne, Fabio Facchetti, Maurilio Ponzoni, Silvia Govi, Andrés J M Ferreri, Manuela Mollejo, Miguel A Piris, Luca Baldini, Jean Soulier, Catherine Thieblemont, Vincenzo Canzonieri, Valter Gattei, Roberto Marasca, Silvia Franceschetti, Gianluca Gaidano, Alessandra Tucci, Silvia Uccella, Maria Grazia Tibiletti, Stephan Dirnhofer, Claudio Tripodo, Claudio Doglioni, Riccardo Dalla Favera, Franco Cavalli, Emanuele Zucca, Ivo Kwee, Francesco Bertoni.   

Abstract

Marginal zone B-cell lymphomas (MZLs) have been divided into 3 distinct subtypes (extranodal MZLs of mucosa-associated lymphoid tissue [MALT] type, nodal MZLs, and splenic MZLs). Nevertheless, the relationship between the subtypes is still unclear. We performed a comprehensive analysis of genomic DNA copy number changes in a very large series of MZL cases with the aim of addressing this question. Samples from 218 MZL patients (25 nodal, 57 MALT, 134 splenic, and 2 not better specified MZLs) were analyzed with the Affymetrix Human Mapping 250K SNP arrays, and the data combined with matched gene expression in 33 of 218 cases. MALT lymphoma presented significantly more frequently gains at 3p, 6p, 18p, and del(6q23) (TNFAIP3/A20), whereas splenic MZLs was associated with del(7q31), del(8p). Nodal MZLs did not show statistically significant differences compared with MALT lymphoma while lacking the splenic MZLs-related 7q losses. Gains of 3q and 18q were common to all 3 subtypes. del(8p) was often present together with del(17p) (TP53). Although del(17p) did not determine a worse outcome and del(8p) was only of borderline significance, the presence of both deletions had a highly significant negative impact on the outcome of splenic MZLs.

Entities:  

Mesh:

Year:  2010        PMID: 21115979     DOI: 10.1182/blood-2010-01-264275

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  37 in total

Review 1.  Molecular pathogenesis of Waldenstrom's macroglobulinemia.

Authors:  Esteban Braggio; Casey Philipsborn; Anne Novak; Lucy Hodge; Stephen Ansell; Rafael Fonseca
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

2.  Genomic profiles of MALT lymphomas: variability across anatomical sites.

Authors:  Ivo Kwee; Paola M V Rancoita; Andrea Rinaldi; Andrés J M Ferreri; Govind Bhagat; Randy D Gascoyne; Vincenzo Canzonieri; Gianluca Gaidano; Claudio Doglioni; Emanuele Zucca; Maurilio Ponzoni; Francesco Bertoni
Journal:  Haematologica       Date:  2011-04-01       Impact factor: 9.941

3.  Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses.

Authors:  Luciano Cascione; Andrea Rinaldi; Alessio Bruscaggin; Chiara Tarantelli; Alberto J Arribas; Ivo Kwee; Lorenza Pecciarini; Afua A Mensah; Valeria Spina; Elaine Y L Chung; Lodovico Terzi di Bergamo; Stephan Dirnhofer; Alexandar Tzankov; Roberto N Miranda; Ken H Young; Alexandra Traverse-Glehen; Gianluca Gaidano; Steven H Swerdlow; Randy Gascoyne; Raul Rabadan; Maurilio Ponzoni; Govind Bhagat; Davide Rossi; Emanuele Zucca; Francesco Bertoni
Journal:  Haematologica       Date:  2019-04-24       Impact factor: 9.941

Review 4.  Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.

Authors:  Kian-Huat Lim; Yibin Yang; Louis M Staudt
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

5.  Expression and function of a novel isoform of Sox5 in malignant B cells.

Authors:  Shanique K E Edwards; Anand Desai; Yan Liu; Carissa R Moore; Ping Xie
Journal:  Leuk Res       Date:  2013-12-25       Impact factor: 3.156

6.  Distinct clinical characteristics draw a new prognostic model for splenic marginal zone lymphoma in HBV high prevalent region.

Authors:  Shuhua Yi; Yuting Yan; Wenjie Xiong; Rui Lv; Zhen Yu; Wei Liu; Enbin Liu; Heng Li; Huimin Liu; Zengjun Li; Gang An; Yan Xu; Kun Ru; Dehui Zou; Lugui Qiu
Journal:  Oncotarget       Date:  2017-10-19

7.  Dissecting the gray zone between follicular lymphoma and marginal zone lymphoma using morphological and genetic features.

Authors:  Oscar Krijgsman; Patricia Gonzalez; Olga Balagué Ponz; Margaretha G M Roemer; Stefanie Slot; Annegien Broeks; Linde Braaf; Ron M Kerkhoven; Freek Bot; Krijn van Groningen; Max Beijert; Bauke Ylstra; Daphne de Jong
Journal:  Haematologica       Date:  2013-07-12       Impact factor: 9.941

8.  Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing.

Authors:  Marina Parry; Matthew Jj Rose-Zerilli; Viktor Ljungström; Jane Gibson; Jun Wang; Renata Walewska; Helen Parker; Anton Parker; Zadie Davis; Anne Gardiner; Neil McIver-Brown; Christina Kalpadakis; Aliki Xochelli; Achilles Anagnostopoulos; Claudia Fazi; David Gonzalez de Castro; Claire Dearden; Guy Pratt; Richard Rosenquist; Margaret Ashton-Key; Francesco Forconi; Andrew Collins; Paolo Ghia; Estella Matutes; Gerassimos Pangalis; Kostas Stamatopoulos; David Oscier; Jonathan C Strefford
Journal:  Clin Cancer Res       Date:  2015-03-16       Impact factor: 12.531

Review 9.  Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review.

Authors:  Michiel van den Brand; J Han J M van Krieken
Journal:  Haematologica       Date:  2013-07       Impact factor: 9.941

10.  The genetics of nodal marginal zone lymphoma.

Authors:  Valeria Spina; Hossein Khiabanian; Monica Messina; Sara Monti; Luciano Cascione; Alessio Bruscaggin; Elisa Spaccarotella; Antony B Holmes; Luca Arcaini; Marco Lucioni; Fabrizio Tabbò; Sakellarios Zairis; Fary Diop; Michaela Cerri; Sabina Chiaretti; Roberto Marasca; Maurilio Ponzoni; Silvia Deaglio; Antonio Ramponi; Enrico Tiacci; Laura Pasqualucci; Marco Paulli; Brunangelo Falini; Giorgio Inghirami; Francesco Bertoni; Robin Foà; Raul Rabadan; Gianluca Gaidano; Davide Rossi
Journal:  Blood       Date:  2016-06-22       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.